Loading clinical trials...
Loading clinical trials...
Maturity onset diabetes of the young (MODY) is a subtype of diabetes which is caused by mutations in specific genes leading to diabetes. The most common cause of MODY is due to mutations in the gene hepatocyte nuclear factor 1 alpha (HNF1A) and is consequently named HNF1A-MODY (or MODY3). HNF1A-MODY is associated with urinary excretion of glucose at lower blood glucose levels compared to other types of diabetes. Normally, glucose is reabsorbed by sodium-glucose cotransporter 2 (SGLT2), but SGLT2 is downregulated due to the mutation in HNF1A. Investigators aim to evaluate the impact of the decreased expression of SGLT2 on glucosuria in patients with HNF1A-MODY compared to patients with type 2 diabetes (T2D) using a single dose of an SGLT2 inhibitor during a glucose clamp experiment.
Participants: Patients with HNF1A-MODY (n=12) and patients with T2D (n=12)
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Steno Diabetes Center Copenhagen
Herlev, Denmark
Start Date
June 22, 2022
Primary Completion Date
June 14, 2023
Completion Date
June 14, 2023
Last Updated
July 27, 2023
21
ACTUAL participants
Hyperglycaemic clamp
OTHER
Placebo
DRUG
Empagliflozin
DRUG
Lead Sponsor
Steno Diabetes Center Copenhagen
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587